openPR Logo
Press release

Non-Cystic Fibrosis Bronchiectasis Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Insmed Inc, AstraZeneca, Zambon, CSL Behring, Chiesi Farmaceutici

05-15-2024 08:39 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Non-Cystic Fibrosis Bronchiectasis Pipeline Drugs Analysis

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Non-Cystic Fibrosis Bronchiectasis pipeline constitutes 16+ key companies continuously working towards developing 17+ Non-Cystic Fibrosis Bronchiectasis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Non-Cystic Fibrosis Bronchiectasis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

"Non-Cystic Fibrosis Bronchiectasis Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Non-Cystic Fibrosis Bronchiectasis Market.

Some of the key takeaways from the Non-Cystic Fibrosis Bronchiectasis Pipeline Report: https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Non-Cystic Fibrosis Bronchiectasis treatment therapies with a considerable amount of success over the years.
• Non-Cystic Fibrosis Bronchiectasis companies working in the treatment market are NovaBiotics Ltd, Synspira Therapeutics, Parion Sciences, Chiesi Farmaceutic, CSL Behring, Haisco Pharmaceutical, SolAeroMed Inc., AstraZeneca, Zambon SpA, Boehringer Ingelheim, Armata Pharmaceuticals, Renovion, and others, are developing therapies for the Non-Cystic Fibrosis Bronchiectasis treatment
• Emerging Non-Cystic Fibrosis Bronchiectasis therapies in the different phases of clinical trials are- NP339, Research Programme:NCFB, Research programme: mucolytic agents, CHF 6333, CSL787, HSK31858, S-1226, Benralizumab, Colistimethate sodium, BI 1291583, AP-PA02, ARINA-1, and others are expected to have a significant impact on the Non-Cystic Fibrosis Bronchiectasis market in the coming years.
• In July 2023, Zambon, a global pharmaceutical company dedicated to innovating treatments and enhancing the health and well-being of patients, revealed the conclusive findings from the Phase 3 PROMIS-I and PROMIS-II studies. These results were unveiled during the 2023 6th World Bronchiectasis Conference held in New York, NY.
• In December 2022, Haisco Pharmaceutical Group Co., Ltd. has commenced a trial titled "Phase 2 Randomized, Double-blind, Placebo-controlled, Multicenter Study." This study aims to evaluate the effectiveness and safety of HSK31858 in individuals diagnosed with Non-cystic Fibrosis Bronchiectasis.
• In April 2022, The FDA awarded breakthrough therapy designation to colistimethate sodium powder intended for nebulization solution to alleviate pulmonary exacerbations in adults afflicted with Non-cystic fibrosis bronchiectasis and Pseudomonas aeruginosa. The basis for the FDA's breakthrough therapy designation was supported by findings from the phase III PROMIS-I study, showcasing that CMS I-neb notably decreased annual rates of pulmonary exacerbations compared to a placebo within this patient population.

Non-Cystic Fibrosis Bronchiectasis Overview
Non-Cystic Fibrosis Bronchiectasis (NCFB) is a chronic lung condition characterized by the permanent dilation and damage of the bronchi, the large airways in the lungs, which leads to frequent lung infections and impaired clearance of mucus. Unlike bronchiectasis caused by cystic fibrosis (CF), NCFB occurs independently of this genetic disorder.

Get a Free Sample PDF Report to know more about Non-Cystic Fibrosis Bronchiectasis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Non-Cystic Fibrosis Bronchiectasis Drugs Under Different Phases of Clinical Development Include:
• NP339: NovaBiotics Ltd
• Research Programme:NCFB: Synspira Therapeutics
• Research programme: mucolytic agents: Parion Sciences
• CHF 6333: Chiesi Farmaceutic
• CSL787: CSL Behring
• HSK31858: Haisco Pharmaceutical
• S-1226: SolAeroMed Inc.
• Benralizumab: AstraZeneca
• Colistimethate sodium: Zambon SpA
• BI 1291583: Boehringer Ingelheim
• AP-PA02: Armata Pharmaceuticals
• ARINA-1: Renovion

Non-Cystic Fibrosis Bronchiectasis Route of Administration
Non-Cystic Fibrosis Bronchiectasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Non-Cystic Fibrosis Bronchiectasis Molecule Type
Non-Cystic Fibrosis Bronchiectasis Products have been categorized under various Molecule types, such as
• Monoclonal antibody
• Small molecule
• Peptide

Non-Cystic Fibrosis Bronchiectasis Pipeline Therapeutics Assessment
• Non-Cystic Fibrosis Bronchiectasis Assessment by Product Type
• Non-Cystic Fibrosis Bronchiectasis By Stage and Product Type
• Non-Cystic Fibrosis Bronchiectasis Assessment by Route of Administration
• Non-Cystic Fibrosis Bronchiectasis By Stage and Route of Administration
• Non-Cystic Fibrosis Bronchiectasis Assessment by Molecule Type
• Non-Cystic Fibrosis Bronchiectasis by Stage and Molecule Type
DelveInsight's Non-Cystic Fibrosis Bronchiectasis Report covers around 17+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Non-Cystic Fibrosis Bronchiectasis product details are provided in the report. Download the Non-Cystic Fibrosis Bronchiectasis pipeline report to learn more about the emerging Non-Cystic Fibrosis Bronchiectasis therapies
https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Non-Cystic Fibrosis Bronchiectasis Therapeutics Market include:
Key companies developing therapies for Non-Cystic Fibrosis Bronchiectasis are - Insmed Incorporated, AstraZeneca, Zambon, CSL Behring, Chiesi Farmaceutici, Haisco Pharmaceutical, Boehringer Ingelheim, Armata Pharmaceuticals, Renovion, SolAeroMed, and others.

Non-Cystic Fibrosis Bronchiectasis Pipeline Analysis:
The Non-Cystic Fibrosis Bronchiectasis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Non-Cystic Fibrosis Bronchiectasis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non-Cystic Fibrosis Bronchiectasis Treatment.
• Non-Cystic Fibrosis Bronchiectasis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Non-Cystic Fibrosis Bronchiectasis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Non-Cystic Fibrosis Bronchiectasis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Non-Cystic Fibrosis Bronchiectasis drugs and therapies
https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Non-Cystic Fibrosis Bronchiectasis Pipeline Market Drivers
• Recent Developments to Improve Research into Bronchiectasis, emergence of Novel Drugs & Therapies with Great Market Potential are some of the important factors that are fueling the Non-Cystic Fibrosis Bronchiectasis Market.

Non-Cystic Fibrosis Bronchiectasis Pipeline Market Barriers
• However, challenges Associated with the Drug Delivery, regulatory & Economic Hindrance and other factors are creating obstacles in the Non-Cystic Fibrosis Bronchiectasis Market growth.

Scope of Non-Cystic Fibrosis Bronchiectasis Pipeline Drug Insight
• Coverage: Global
• Key Non-Cystic Fibrosis Bronchiectasis Companies: NovaBiotics Ltd, Synspira Therapeutics, Parion Sciences, Chiesi Farmaceutic, CSL Behring, Haisco Pharmaceutical, SolAeroMed Inc., AstraZeneca, Zambon SpA, Boehringer Ingelheim, Armata Pharmaceuticals, Renovion, and others
• Key Non-Cystic Fibrosis Bronchiectasis Therapies: NP339, Research Programme:NCFB, Research programme: mucolytic agents, CHF 6333, CSL787, HSK31858, S-1226, Benralizumab, Colistimethate sodium, BI 1291583, AP-PA02, ARINA-1, and others
• Non-Cystic Fibrosis Bronchiectasis Therapeutic Assessment: Non-Cystic Fibrosis Bronchiectasis current marketed and Non-Cystic Fibrosis Bronchiectasis emerging therapies
• Non-Cystic Fibrosis Bronchiectasis Market Dynamics: Non-Cystic Fibrosis Bronchiectasis market drivers and Non-Cystic Fibrosis Bronchiectasis market barriers

Request for Sample PDF Report for Non-Cystic Fibrosis Bronchiectasis Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Non-Cystic Fibrosis Bronchiectasis Report Introduction
2. Non-Cystic Fibrosis Bronchiectasis Executive Summary
3. Non-Cystic Fibrosis Bronchiectasis Overview
4. Non-Cystic Fibrosis Bronchiectasis- Analytical Perspective In-depth Commercial Assessment
5. Non-Cystic Fibrosis Bronchiectasis Pipeline Therapeutics
6. Non-Cystic Fibrosis Bronchiectasis Late Stage Products (Phase II/III)
7. Non-Cystic Fibrosis Bronchiectasis Mid Stage Products (Phase II)
8. Non-Cystic Fibrosis Bronchiectasis Early Stage Products (Phase I)
9. Non-Cystic Fibrosis Bronchiectasis Preclinical Stage Products
10. Non-Cystic Fibrosis Bronchiectasis Therapeutics Assessment
11. Non-Cystic Fibrosis Bronchiectasis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Non-Cystic Fibrosis Bronchiectasis Key Companies
14. Non-Cystic Fibrosis Bronchiectasis Key Products
15. Non-Cystic Fibrosis Bronchiectasis Unmet Needs
16 . Non-Cystic Fibrosis Bronchiectasis Market Drivers and Barriers
17. Non-Cystic Fibrosis Bronchiectasis Future Perspectives and Conclusion
18. Non-Cystic Fibrosis Bronchiectasis Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Non-Cystic Fibrosis Bronchiectasis Market https://www.delveinsight.com/report-store/non-cystic-fibrosis-bronchiectasis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Non-Cystic Fibrosis Bronchiectasis Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Non-Cystic Fibrosis Bronchiectasis Epidemiology https://www.delveinsight.com/report-store/non-cystic-fibrosis-bronchiectasis-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Non-Cystic Fibrosis Bronchiectasis Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:

Aneurysmal Subarachnoid Hemorrhage Market https://www.delveinsight.com/report-store/aneurysmal-subarachnoid-hemorrhage-sah-market
DelveInsight's "Aneurysmal Subarachnoid Hemorrhage (SAH) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Aneurysmal Subarachnoid Hemorrhage (SAH), historical and forecasted epidemiology as well as the Aneurysmal Subarachnoid Hemorrhage (SAH) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Angelman Syndrome Market https://www.delveinsight.com/report-store/angelman-syndrome-market-forecast
DelveInsight's "Angelman Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Angelman Syndrome, historical and forecasted epidemiology as well as the Angelman Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Autoimmune Pulmonary Alveolar Proteinosis Market https://www.delveinsight.com/report-store/autoimmune-pulmonary-alveolar-proteinosis-apap-market
DelveInsight's "Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Market Insights, Epidemiology and Market Forecast - 2032" report delivers an in-depth understanding of Autoimmune pulmonary alveolar proteinosis, historical and forecasted epidemiology as well as Autoimmune pulmonary alveolar proteinosis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Cardiovascular Calcification Market https://www.delveinsight.com/report-store/cardiovascular-calcification-market
DelveInsight's "Cardiovascular Calcification Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Cardiovascular Calcification, historical and forecasted epidemiology as well as the Cardiovascular Calcification market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Charcot Marie Tooth Disease Market https://www.delveinsight.com/report-store/charcot-marie-tooth-disease-market
DelveInsight's 'Charcot-Marie-Tooth Disease Market Insights, Epidemiology, and Market Forecast 2032' report deliver an in-depth understanding of the Charcot-Marie-Tooth Disease, historical and forecasted epidemiology as well as the Charcot-Marie-Tooth Disease market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Non-Cystic Fibrosis Bronchiectasis Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Insmed Inc, AstraZeneca, Zambon, CSL Behring, Chiesi Farmaceutici here

News-ID: 3498134 • Views:

More Releases from DelveInsight Business Research

Low Grade Glioma Market to Register Incremental Growth During the Forecast Period (2024-2034), Asserts DelveInsight | Day One Biopharma, Servier, SpringWorks Therapeutics, AnHeart Therapeutics, Beigene
Low Grade Glioma Market to Register Incremental Growth During the Forecast Perio …
DelveInsight's "Low Grade Glioma Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Low Grade Glioma, historical and forecasted epidemiology as well as the Low Grade Glioma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Low Grade Glioma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Low Grade Glioma
Achromatopsia Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Applied Genetic Technologies Crp, MeiraGTx and Janssen Pharmaceuticals
Achromatopsia Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest …
DelveInsight's "Achromatopsia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Achromatopsia, historical and forecasted epidemiology as well as the Achromatopsia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Achromatopsia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Achromatopsia Market Forecast https://www.delveinsight.com/sample-request/achromatopsia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the key facts of the Achromatopsia
Achondroplasia Market to Witness Upsurge in Growth During the Forecast Period (2023-2032), Examine DelveInsight | BridgeBio/ QED Therapeutics , Ribomic Inc, Sanofi, Changchun GeneScience Pharma, QED Therapeutics, Inc., Ascendis Pharma A/S, QED Therapeutic
Achondroplasia Market to Witness Upsurge in Growth During the Forecast Period (2 …
DelveInsight's "Achondroplasia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Achondroplasia, historical and forecasted epidemiology as well as the Achondroplasia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Achondroplasia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Achondroplasia Market Forecast https://www.delveinsight.com/sample-request/achondroplasia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the key facts of the Achondroplasia
Acanthamoeba Keratitis Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032), States DelveInsight | SIFI
Acanthamoeba Keratitis Market is Expected to Expand at a Healthy Growth Rate Dur …
The Acanthamoeba Keratitis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Acanthamoeba Keratitis pipeline products will significantly revolutionize the Acanthamoeba Keratitis market dynamics. DelveInsight's "Acanthamoeba Keratitis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Acanthamoeba Keratitis, historical and forecasted epidemiology as well as the Acanthamoeba Keratitis market trends in the United

All 5 Releases


More Releases for Bronchiectasis

Bronchiectasis Global Market Research Report 2025
Bronchiectasis Report by Material, Application, and Geography � Global Forecast to 2022 is a professional and in-depth research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, united Kingdom, Japan, South Korea and China). Access more details about this report at: https://www.research2reports.com/report-medical-devices/bronchiectasis-market/80987 The report firstly introduced the Bronchiectasis basics: definitions, classifications, applications and market overview; product
Bronchiectasis - Market Insights, Epidemiology and Market Forecast 2018-2027
Bronchiectasis Market: WiseGuyReports.com adds “Bronchiectasis Market 2018 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting 2027” reports tits database. Executive Summary “Bronchiectasis - Market Insights, Epidemiology and Market Forecast – 2027” report provides the detailed overview of the disease and in depth understanding of historical and forecasted epidemiology. It highlights the existing treatment patterns, potential upcoming drugs and also identifies best of the market opportunities by providing the current and forecasted market
Bronchiectasis Therapeutics Analysis - Clinical Trials & Results, Collaboration …
The study analysed that the Bronchiectasis therapeutics pipeline comprises approximately 13 drug candidates in different stages of development. Bronchiectasis is a condition in which damage to the airways causes them to widen and become flabby and scarred. The airways are tubes that carry air in and out of lungs. Bronchiectasis usually is the result of an infection or other condition that injures the walls of airways or prevents the airways
Bronchiectasis Market To Discern Magnified Growth During 2025
Bronchiectasis is a chronic and life-threatening disease, wherein parts of airways of lungs are permanently enlarged. This condition damages the bronchial tubes of lungs permanently and also widens, and thickens them. Inflammation and infection in the bronchi leads to this condition. The severity of bronchiectasis symptoms may vary widely. The most common symptom of bronchiectasis is breathlessness i.e., difficulty in breathing or feeling short of breath, frequent chest infections, and
Bronchiectasis Treatment Market Foraying into Emerging Economies 2017 - 2025
Bronchiectasis refers to a condition characterized by damaged airways (tubes) and affect their ability to clear out the mucus. This deposition of mucus leads to bacterial infections and hence resulting in serious and repeated lung infections. Bronchiectasis is a long term condition resulting in serious health conditions such as heart failure and respiratory failure. Mucus producing cough is the major symptom of this condition. Request for Table of Contents @ https://www.persistencemarketresearch.com/toc/21037
Bronchiectasis Therapeutics Clinical Trials, Pipeline Analysis & Collaboration
Bronchiectasis is a condition in which damage to the airways causes them to widen and become flabby and scarred. The airways are tubes that carry air in and out of lungs. Bronchiectasis usually is the result of an infection or other condition that injures the walls of airways or prevents the airways from clearing mucus. In bronchiectasis, the airways slowly lose their ability to clear out mucus. When mucus cannot